Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 0.58 |
| ▸ | SLC6A2 | P23975 | 9/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.51 |
| ▸ | HTR1A | P08908 | 6/20 | 0.48 |
| ▸ | HTR6 | P50406 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | FPR1 | P21462 | 2/20 | 0.45 |
| ▸ | FPR2 | P25090 | 1/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | JAK3 | P52333 | 1/20 | 0.43 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1515977 | 0.83 | PTGDR2 (0.49) | MEN1KMT2A | |
| SCHEMBL2707057 | 0.82 | HTR2C (0.63) | HTR2CSLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL5584891 | 0.82 | HTR2C (0.59) | HTR2CSLC6A2SLC6A4SLC6A3HTR6 | |
| SCHEMBL28695051 | 0.82 | CPS1 (0.41) | HTR2CSLC6A2SLC6A4SLC6A3MEN1 | |
| Hydrochloric Acid SCHEMBL4890713 | 0.82 | SLC6A2 (0.47) | HTR2CSLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL21341944 | 0.82 | HTR2A (0.55) | HTR2CHTR1AHTR6MEN1KMT2A | |
| SCHEMBL22324792 | 0.81 | HTR2C (0.58) | HTR2CSLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL28710780 | 0.81 | FFAR1 (0.38) | MEN1KMT2AFPR1FPR2 | |
| SCHEMBL28714410 | 0.80 | FFAR1 (0.44) | — | |
| SCHEMBL19988384 | 0.80 | MTNR1A (0.49) | HTR2CMEN1KMT2AFPR1FPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479816-B2 | 20-HETE formation inhibitors | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2025-11-25 | — | — | US | disclosed |
| US-20220144797-A1 | 20-HETE FORMATION INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2022-05-12 | — | — | US | disclosed |
| US-20220144797-A1 | 20-HETE FORMATION INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2022-05-12 | — | — | US | disclosed |
| WO-2020163689-A1 | 20-HETE FORMATION INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2020-08-13 | — | — | WO | disclosed |
| WO-2020163689-A1 | 20-HETE FORMATION INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2020-08-13 | — | — | WO | disclosed |
| US-8440702-B2 | 1,3-oxazolidin -2-one derivatives useful as CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-05-14 | — | — | US | disclosed |
| US-8440702-B2 | 1,3-oxazolidin -2-one derivatives useful as CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-05-14 | — | — | US | disclosed |
| US-8440702-B2 | 1,3-oxazolidin -2-one derivatives useful as CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-05-14 | — | — | US | disclosed |
| EP-2029560-B1 | 1,3-OXAZOLIDIN-2-ONE DERIVATIVES USEEFUL AS CETP INHIBITORS | MERCK SHARP & DOHME (US) | 2013-04-24 | — | — | EP | disclosed |
| EP-2029560-B1 | 1,3-OXAZOLIDIN-2-ONE DERIVATIVES USEEFUL AS CETP INHIBITORS | MERCK SHARP & DOHME (US) | 2013-04-24 | — | — | EP | disclosed |
| US-20110178059-A1 | 1,3-OXAZOLIDIN -2-ONE DERIVATIVES USEFUL AS CETP INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-07-21 | — | — | US | disclosed |
| US-20110178059-A1 | 1,3-OXAZOLIDIN -2-ONE DERIVATIVES USEFUL AS CETP INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-07-21 | — | — | US | disclosed |
| US-20110178059-A1 | 1,3-OXAZOLIDIN -2-ONE DERIVATIVES USEFUL AS CETP INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-07-21 | — | — | US | disclosed |
| US-7915271-B2 | 1,3-oxazolidin-2-one derivatives useful as CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2011-03-29 | — | — | US | disclosed |
| US-20090137548-A1 | 1,3-Oxazolidin-2-One Derivatives Useful as Cetp Inhibitors | MERCK SHARP & DOHME LLC | 2009-05-28 | — | — | US | disclosed |
| EP-2029560-A2 | 1,3-OXAZOLIDIN-2-ONE DERIVATIVES USEEFUL AS CETP INHIBITORS | Merck & Co., Inc. (US) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007079186-A2 | 1, 3-OXAZOLIDIN-2-ONE DERIVATIVES USEFUL AS CETP INHIBITORS | MERCK & CO., INC. (US) | 2007-07-12 | — | — | WO | disclosed |
| WO-2007079186-A2 | 1, 3-OXAZOLIDIN-2-ONE DERIVATIVES USEFUL AS CETP INHIBITORS | MERCK & CO., INC. (US) | 2007-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178059-A1 | 1,3-OXAZOLIDIN -2-ONE DERIVATIVES USEFUL AS CETP INHIBITORS | CETP, MTTP, APOB | HTR2C 4713/4885SLC6A2 4671/4885SLC6A4 4737/4885 |
| US-20220144797-A1 | 20-HETE FORMATION INHIBITORS | CYP4A22, ALOX5, ALOX15 | HTR2C 235/4885SLC6A2 1927/4885SLC6A4 452/4885 |
| US-12479816-B2 | 20-HETE formation inhibitors | CYP4A22, ALOX5, ALOX15 | HTR2C 235/4885SLC6A2 1927/4885SLC6A4 452/4885 |
| US-20090137548-A1 | 1,3-Oxazolidin-2-One Derivatives Useful as Cetp Inhibitors | CETP, MTTP, APOB | HTR2C 4713/4885SLC6A2 4671/4885SLC6A4 4737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.